These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27057541)

  • 21. Free terminal time optimal control problem of an HIV model based on a conjugate gradient method.
    Jang T; Kwon HD; Lee J
    Bull Math Biol; 2011 Oct; 73(10):2408-29. PubMed ID: 21271294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Control of a Delayed SIRS Epidemic Model with Vaccination and Treatment.
    Laarabi H; Abta A; Hattaf K
    Acta Biotheor; 2015 Jun; 63(2):87-97. PubMed ID: 25578405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-Term Antiretroviral Treatment Recommendations Based on Sensitivity Analysis of a Mathematical Model for HIV Infection of CD₄⁺Τ Cells.
    Croicu AM; Jarrett AM; Cogan NG; Hussaini MY
    Bull Math Biol; 2017 Nov; 79(11):2649-2671. PubMed ID: 28940123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunologic control of HIV-1.
    Gandhi RT; Walker BD
    Annu Rev Med; 2002; 53():149-72. PubMed ID: 11818468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance, remission, and qualitative differences in HIV chemotherapy.
    Kirschner DE; Webb GF
    Emerg Infect Dis; 1997; 3(3):273-83. PubMed ID: 9284371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.
    Trono D; Van Lint C; Rouzioux C; Verdin E; Barré-Sinoussi F; Chun TW; Chomont N
    Science; 2010 Jul; 329(5988):174-80. PubMed ID: 20616270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player.
    Khoury G; Rajasuriar R; Cameron PU; Lewin SR
    Clin Immunol; 2011 Dec; 141(3):253-67. PubMed ID: 21996455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus.
    Rouzine IM; Sergeev RA; Glushtsov AI
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):666-71. PubMed ID: 16407101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging race to cure HIV infections.
    Cohen J
    Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173
    [No Abstract]   [Full Text] [Related]  

  • 30. The problem with antivirals alone.
    TreatmentUpdate; 1999 Mar; 11(2):1-2. PubMed ID: 11366774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
    Ho DD; Neumann AU; Perelson AS; Chen W; Leonard JM; Markowitz M
    Nature; 1995 Jan; 373(6510):123-6. PubMed ID: 7816094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2004 Sep; 66(5):1259-83. PubMed ID: 15294425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
    Monie D; Simmons RP; Nettles RE; Kieffer TL; Zhou Y; Zhang H; Karmon S; Ingersoll R; Chadwick K; Zhang H; Margolick JB; Quinn TC; Ray SC; Wind-Rotolo M; Miller M; Persaud D; Siliciano RF
    J Virol; 2005 Apr; 79(8):5185-202. PubMed ID: 15795302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mathematical modelling of the impact of haematopoietic stem cell-delivered gene therapy for HIV.
    Murray JM; Fanning GC; Macpherson JL; Evans LA; Pond SM; Symonds GP
    J Gene Med; 2009 Dec; 11(12):1077-86. PubMed ID: 19777528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection dynamics in HIV-specific CD4 T cells: does a CD4 T cell boost benefit the host or the virus?
    Wodarz D; Hamer DH
    Math Biosci; 2007 Sep; 209(1):14-29. PubMed ID: 17379260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic multidrug therapies for HIV: a control theoretic approach.
    Wein LM; Zenios SA; Nowak MA
    J Theor Biol; 1997 Mar; 185(1):15-29. PubMed ID: 9093552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamics of HIV infection in lymphoid tissue network.
    Nakaoka S; Iwami S; Sato K
    J Math Biol; 2016 Mar; 72(4):909-938. PubMed ID: 26507442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
    Moriuchi H; Moriuchi M
    Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.